James Markert, MD
Affiliations: | 2006- | Neurosurgery | University of Alabama, Birmingham, Birmingham, AL, United States |
Google:
"James Markert"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gross EG, Hamo MA, Estevez-Ordonez D, et al. (2023) Oncolytic virotherapies for pediatric tumors. Expert Opinion On Biological Therapy. 1-17 |
| Kang KD, Bernstock JD, Totsch SK, et al. (2022) Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Ghajar-Rahimi G, Kang KD, Totsch SK, et al. (2022) Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacology & Therapeutics. 239: 108193 |
| Quinn CH, Beierle AM, Hutchins SC, et al. (2022) Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy. Cancers. 14 |
| Miller KE, Cassady KA, Roth JC, et al. (2022) Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 28: 498-506 |
| Friedman GK, Johnston JM, Bag AK, et al. (2021) Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. The New England Journal of Medicine |
| Kang K, Bernstock J, Mott B, et al. (2021) EPCT-22 SAFETY AND EFFICACY OF INTRAVENTRICULAR IMMUNOVIROTHERAPY WITH ONCOLYTIC HSV-1 G207 FOR TREATMENT OF LEPTOMENINGEAL DISEASE Neuro-Oncology. 23: i51-i52 |
| Chambers MR, Bentley RT, Crossman DK, et al. (2020) The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery. 7: 59 |
| Bastola S, Pavlyukov MS, Yamashita D, et al. (2020) Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660 |
| Bernstock JD, Bag A, Fiveash J, et al. (2020) Design and Rationale for First-In-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Human Gene Therapy |